Revolution Medicines price target raised to $44 from $28 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines to $44 from $28 and keeps a Buy rating on the shares. The company has two potentially registrational trials slated to start in 2024, the analyst tells investors in a research note. The firm says Revolution’s balance sheet strength should provide an operational runway well beyond 2025 and through multiple key data catalysts “constituting value inflection points.”